SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing

HOUSTON, April 28 /PRNewswire/ — SeqWright Inc., a CLIA certified and GLP compliant provider of custom genomic and molecular biology services, announced today its entry into the genetically-targeted therapy field through its partnership with PharmaGenoma. SeqWright will be the exclusive genetic testing provider for PharmaGenoma’s HairDX test which evaluates patient responsiveness to the common hair loss treatment, Finasteride.

Finasteride is a commonly prescribed medication for the treatment of Androgenic Alopecia (AGA) or common hair loss. The treatment works by blocking the production of dihydrotesterone (DHT), which is responsible for the loss of hair. However, due to potential Finasteride side effects, along with variations in responsiveness, many patients are reluctant to begin or continue treatment. In order to overcome this obstacle, HairDX developed a genetic test for Finasteride response which will allow patients to determine if treatment benefits outweigh potential side effects prior to beginning a Finasteride regimen.

“The state of the art research facility at SeqWright was essential to achieving our goals of high quality genetic analysis combined with a turn-around time useful for clinicians,” said PharmaGenoma, CEO Andy Goren.

About SeqWright

Based in Houston, TX, SeqWright Incorporated is recognized as an international leader in the field of contract genomic services, inclucing next generation sequencing. For over fifteen years, SeqWright has provided state-of-the-art Molecular Biology and Genomic services, from small projects up to full clinical trials. SeqWright was recently awarded a license by the state of California to operate as a clinical laboratory. This license, along with its CLIA certification, allows SeqWright to handle clinical samples from the vast majority of the United States. For additional information about SeqWright and its services, please visit www.seqwright.com.

About PharmaGenoma, Inc.

PharmaGenoma, Inc. Based in Irvine, CA, USA is a molecular dermatology research and development company. PharmaGenoma and its subsidary HairDX market the first genetic test for male and female hair loss. The company is dedicated to the research and development of new prescription based therapies tailored to an individual’s genetic make up. PharmaGenoma uses only CLIA certified laboratories (Clinical Laboratory Improvement Amendments) to perform the genetic analysis. The HairDX test collection kit is listed with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and the United States Food and Drug Administration (FDA) as a Class I medical device.

SOURCE SeqWright Inc.